Possia (ticagrelor)
- Region
- 🇪🇺 EU
- Active substance
- ticagrelor
- Company
- AstraZeneca AB
- Status
- Withdrawn
- Therapeutic area
- Peripheral Vascular Diseases; Acute Coronary Syndrome
- EU approval
- Fri 03 Dec 2010
- Application
- EMEA/H/C/002303
- ATC
- B01AC24
- Official record
- www.ema.europa.eu
Indication
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Brilique Authorised · AstraZeneca AB
Follow Possia
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.